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Abstract
Background: A multicentre cohort study was held in Morocco, designed to evaluate the quality of life of cancer
patients. The aim of this paper is to report the assessment of the quality of life of early colorectal cancer patients,
before and after cancer treatment, to identify other factors which are related to this quality of life.
Methods: We used the third version of the QLQ-C30 questionnaire of the European organization for Research and
treatment of Cancer (EORTC) after a transcultural validation. The Data collection was done at inclusion and then
every twelve weeks to achieve one year of follow up.
Results: Overall 294 patients presented with early colorectal cancer, the median age was 56 years (range: 21–88).
The male–female sex ratio was 1.17. At inclusion, the global health status was the most affected functional
dimension. For symptoms: financial difficulties and fatigue scores were the highest ones. Emotional and social
functions were significantly worse in rectal cancer. Most symptoms were more present in rectal cancer. At inclusion,
global health status score was significantly worse in stage III. Anorexia was significantly more important among
colorectal female patients. For Patients over 70 years-old, the difference was statistically significant for the physical
function item which was lower. Overall, Functional dimensions scores were improved after chemotherapy. The
symptoms scores did not differ significantly for patients treated by radiotherapy, between inclusion and at one year.
Conclusion: Our EORTC QLQ C30 scores are overall comparable to the reference values. Neither chemotherapy, nor
radiotherapy worsened the quality of life at one year.
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Background
Colorectal cancer is frequent in western countries, it
represents the third most common cancer in France,
with approximately 40 000 new cases per year [1]. Ac-
cording to Moroccan registries, it represents the first
gastro-intestinal cancer before gastric cancer, and the
fourth most common cancer, with an incidence of 8,4/
100 000 habitants in 2007 [2]. This incidence have
increased these last years (it was 6.9/100 000 habitants
in 2005) [2]. This could be explained by the fact that
Morocco has experienced, over the past 5 years,
considerable progress in the detection, diagnosis and
treatment of cancer. Many anticancer centers, equipped
with the latest technologies have been constructed, most
of anti-cancer drugs are available, and a national cancer
plan (2010–2019) has been established.
When improving treatment of cancer, quality of life
(QOL) becomes an important parameter to assess. It
permits the evaluation of the impact of cancer and its
treatment on the overall life of patients.
A multicentre cohort study was held in Morocco,
designed to evaluate the quality of life of Moroccan can-
cer patients, including colorectal, cervical, breast and
lung cancer [3, 4]. It is a prospective multicentre cohort
study, performed in the ten existing oncological centers
in Morocco.
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The aim of this paper is to report the assessment of
the quality of life of early colorectal cancer patients, be-
fore and after specific cancer treatment (chemotherapy
and/or radiotherapy), to identify other factors which
are related to this quality of life (age, sex, localization:
colon or rectum, performance status, disease stage), to
describe Moroccan cancer patients characteristics.
Methods
Study design and study population
This is a Moroccan multicentre prospective cohort
study. Patients were included, between December 2009
and December 2011, in the ten existing cancer centers
in Morocco: seven public institutions (National Insti-
tute of oncology and Mohammed V military hospital
in Rabat, Ibn rochd University hospital in Casablanca,
Oujda, Agadir, Marrakech, Fez) and 3 private cancer
clinics (Al Kindy and le Littoral in Casablanca, Nakhil
in Rabat).
All patients were adults of 18 years or older, newly
diagnosed with a histologically proven colorectal cancer.
The diagnosis had to be made in less than three months
before inclusion. Patients operated for their cancers
within 3 months before inclusion were eligible to enter
the study. A written informed consent was required for
enrolment in the study, after the patient has received all
the informations regarding the conditions of the study.
Ethical approval was obtained from the ethics commit-
tees of the University Hospital Center Hassan II in Fez.
Patients who received a specific treatment, chemother-
apy or radiotherapy, and those with major neuropsycho-
logical defect were excluded.
In this paper we report quality of life assessment of
early stage colorectal cancer patients which was defined
by localized, stage I-II and III, colorectal cancer. Meta-
static colorectal cancer (stage IV) was excluded, and will
be separately analyzed, because patients are treated in a
palliative setting, with systemic therapy and all patients
remain under treatment at one year.
Collection data procedure
Questionnaires and data collection
We used the third version of the QLQ-C30 questionnaire
of the European organization for Research and treatment
of Cancer (EORTC). It is a validated tool for the assess-
ment of QoL in cancer patients. It contains 14 items: 5 of
them are related to activity (Physical, professional and
leisure, cognitive, emotional and social functioning), 3 of
them to symptoms (Asthenia, pain, nauseas and vomiting)
and the remaining six are independent items evaluating
other symptoms (dyspnea, insomnia, appetite loss, consti-
pation, diarrhea, and financial difficulties). The QLQ-C30
was used after a transcultural validation [3]. It was devel-
oped according to Beaton and al recommendations [5].
The QLQ-C30 is a self-reporting questionnaire; how-
ever it was administered to illiterate patients by trained
interviewers. The Data collection was done at inclusion
and then every three months to each patient, until one
year of follow-up.
All socio-demographic, economic and therapeutic
data were extracted for colorectal cancer : age, gender,
geographic origin, marital status, profession, income,
level of education, medical insurance, localization,
histological subtype, Tumor-Node-Metastasis (TNM)
staging, evaluation of performance status according to
Eastern Cooperative Oncology Group (ECOG) criteria,
treatment (surgery, pre-operative radiotherapy or con-
current chemo-radiation for rectal cancer, adjuvant
chemotherapy).
Statistical methods
 Calculation of EORTC QLQ-C30 scores [6]:
Scores of the items were linearly transformed to a
scale from 0 to 100. A high score for a functional scale
represents a healthy level of functioning, a high score for
the global health status represents a high quality of life,
but a high score for a symptom item represents a high
level of symptomatology.
 Descriptive analysis
Descriptive analysis was performed for sociodemo-
graphic and clinical features, with a confidence interval
defined at 95 %. To describe the quality of life scores, we
calculated the means and standard deviations, minimum
and maximum.
 Univariate analysis:
At inclusion, a global analysis was conducted in the
whole population of early colorectal patients. Subgroup
analyses were performed according to some variables: age,
gender, tumor location (colon versus rectum), perform-
ance status (PS ≤ 1 versus >1) and stage. The comparison
between subgroups was performed by t-tests and one-way
ANOVA. A p-value of less than 0.05 was considered as
statistically significant. To assess the scores variability of
quality of life between inclusion (before treatment:
chemotherapy or radiotherapy) and at 1 year (after treat-
ment), we used the paired Student’s t-test. The statistical
analysis was performed by SPSS, version 17.0, software.
Results
Overall 2903 cancer patients were recruited, among
whom 461 patients presented with colorectal cancer, 294
(63.7 %) were diagnosed at an early stage (I, II or III).
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Socio-demographic and clinical characteristics of early
colorectal cancer patients
Two hundred ninety-four patients with an early stage
colorectal cancer were included in the study, of which
there were 161 colon cancers (54.7 %) and 133 rectal
cancers (45.3 %). The median age at diagnosis was
56 years (range: 21–88). The male–female sex ratio was
1.17. Majority of patients came from urban areas
(78.2 %), a significant number were illiterate (49 %), and
only 7.5 % had a high level of education. 32.7 % of pa-
tients were professionally active, but the majority of
them had a low-intermediate socio-economic status.
About 60 % of patients had no medical insurance. Eighty
percent were married (see Table 1).
Tumor-node-metastasis staging system was as follows:
Stage I = 19 (6.5 %), stage II = 80 (27.2 %), stage III = 195
(66.3 %). One hundred and ninety eight patients (67.3 %)
patients received adjuvant chemotherapy based on the
combination of capecitabin and Oxaliplatin every three
weeks, during 6 months (eight cycles). Among rectal
cancer patients (133), 50 (37.5 %) received pre-operative
radiotherapy, which was concomitant to chemotherapy
in 40 patients. (See Table 2).
This study have some limitations: mainly data concern-
ing surgery are missed. The surgery have been performed,
in majority of patients (223) (except those treated by pre-
operative radiotherapy) before inclusion in the study. At
inclusion, 50 patients presenting with rectal cancer have
not been operated because they were candidate for pre-
operative radiotherapy. The surgical procedure was un-
known in 37 % of patients (Table 2). Therefore, the QOL
have not been assessed before surgical treatment.
QOL assessment
At inclusion, all patients were assessed before receiving
any specific treatment: radiotherapy or chemotherapy.
At inclusion, the global health status was the most
affected functional dimension (score 62.84). For symp-
toms: financial difficulties and fatigue scores were the
highest ones (61.72 and 38.21 respectively). The scores
at inclusion are summarized in Tables 3 and 4.
Localization specific scores
The global health status had the lowest score at inclu-
sion for both colon and rectal cancer patients. The less
affected dimension was the cognitive function (scores
86 and 85 for colon and rectal cancers respectively).
Differences were statistically significant between the
two localizations for emotional and social functions.
They were worse in rectal cancer (61 vs 68 and 76 vs
85 respectively) (see Table 3).
Most symptoms were more present in rectal cancer. The
difference was statistically significant for Nauseas, pain, in-
somnia, anorexia, constipation and diarrhea (See Table 4).
Stage specific scores
At inclusion, global health status score was significantly
worse in stage III (p = 0.003). Moreover, Role, emotional
and cognitive functions were more altered in stage III
Table 1 Sociodemographic characteristics of colorectal cancer
patients at inclusion, Morocco, 2009–2011
No (total 294) %
Age (median) 56 years (range : 21–88)
Sex
• Male 159 54.1
• Female 135 45.9
Living environment
• Urban 204 78.2
• Rural 57 21.8
Residency
• Casablanca 29 10.2
• Rabat 33 11.6
• Agadir 9 3.2
• Meknes 9 3.2
• Kenitra 9 3.2
• Marrakech 35 12.3
• Others 170 57.9
Education
• Illiterate 144 49.0
• Primary school 55 18.7
• College 73 24.8
• High school 22 7.5
Marital status
• Single 32 10.9
• Married 235 80
• Divorced 10 3.4
• Widower 17 5.8
Professional Status
• Working 96 32.7
• Retired 41 13.9
• Without profession 49 16.7
• Housewife 106 36.1
• Student 2 0.7
Socioeconomic Status
• Low 142 48.3
• Intermediate 141 48.0
• High 11 3.7
Medical insurance
• Public health-insurance 108 36.7
• Private insurance 10 3.4
• No medical insurance 176 59.9
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colorectal cancer but the difference was not statistically
significant (see Table 3). In addition to financial diffi-
culties, the prominent symptom in all stages was the
fatigue. The scores were 37, 39 and 36 for stages I, II
and III respectively. Curiously, nausea was significantly
higher in stage I (See Table 4).
Sex specific scores
Overall, women had more altered functional functions
and more permanent symptoms (see stables 3 and 4).
Anorexia was significantly more prevalent among colo-
rectal female patients (28 versus 37) (see Table 4).
Age specific scores
Patients over 70 years-old had lower scores, for global
health status, physical role and cognitive functions. The
difference was statistically significant for the physical
function item (see Table 3). Major symptoms in all age
subgroups were financial difficulties (scores ranges
between 57 and 65) and fatigue (scores 36 to 44). There
was no significant difference between symptoms accord-
ing to the age range. Nevertheless, descriptive data sug-
gested that patients of more than 70 years-old had
higher scores of pain, dyspnea and constipation. Patients
between 60 and 69 years-old had more diarrheas while
patients less than 50 years-old had higher scores of nau-
seas and insomnia (see Table 4).
Performance status (PS) specific scores
Majority of patients had PS >1 (67.9 %) at inclusion (see
Table 2). Except for the emotional function, all of the
functional dimensions were significantly more altered in
patients with PS > 1 (see Table 3). In the same way, most
symptoms scores were higher in “PS > 1” patients. The
difference was statistically significant apart from dyspnea,
diarrhea and financial difficulties (see Table 4).
Evolution according to treatment
Overall, Functional dimensions scores were improved
after the end of chemotherapy. However, this improve-
ment was significant only for global health status and
role functioning (66.93 vs 73.4 and 70 vs 79.8 respect-
ively) (Fig. 1). A trend to an improvement was also seen
for symptoms. The scores of fatigue, pain, appetite loss,
constipation and diarrhea significantly decreased after
completion of chemotherapy (Fig. 2).
Curiously, the cognitive function was the only dimen-
sion which had a statistically significant variation. The
cognitive capacities were altered after treatment by
radiotherapy (91 vs 80 p = 0.04) (Fig. 3). Likewise, except
for constipation, the symptoms scores did not differ sig-
nificantly for patients treated by radiotherapy, between
inclusion and at one year (Fig. 4). The constipation score
fell from 38 to 13.33 (p = 0.005). Moreover, there was a
borderline trend to an improvement in pain scores (40
vs 24.16 p = 0.054) (Fig. 4).
When we look to the evolution of QOL scores every
three months: overall, functional dimensions were stable
at 12 weeks and have started to improve thereafter.
The global health status began to improve after inclu-
sion, whereas social function has slightly worsened at
12 weeks and increased thereafter (Fig. 5). Majority of
symptoms were also stable at 12 weeks and decreased
with time. Some symptoms have started to improve at
12 weeks like pain and constipation. Nausea was the
only symptom that worsened at 12 weeks and improved
thereafter (Fig. 6).
Discussion
This is the first large prospective study assessing the
quality of life of early colorectal cancer patients, in
Morocco, and also in North Africa. The objective of this
study was also to compare quality of life, before and
after specific cancer treatment (chemotherapy and/or
radiotherapy), at one year, when acute treatment effects
are expected to have declined, to identify other factors
which are related to this quality of life (age, sex,
localization: colon or rectum, performance status, dis-
ease stage), to describe Moroccan cancer patients char-
acteristics. In our study, the global health status was the
most affected functional dimension at inclusion. For
symptoms: financial difficulties and fatigue scores were
Table 2 Clinical features of early colorectal cancer patients,
Morocco, 2009–2011
No (total 294) %
Localization
• Colon 161 54.7
• Rectum 133 45.3
TNM Staging
• Stage I 19 6.5
• Stage II 80 27.2
• Stage III 195 66.3
Surgery
• Radical surgery 113 38.4
• Conservative surgery 67 22.8
• Palliative surgery 5 1.7




• Performed 50 37.5
• Not performed 83 62.5
Adjuvant chemotherapy
• Performed 198 67.3
• Not performed 77 26.2
• Unknown 19 6.5
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the main factors affecting colorectal cancer patient’s Qol.
The most important factors affecting Qol were: rectal
location, advanced disease (stage III). The impact of age
and gender on Qol was less important, mainly the
impact of advanced age was equivocal.
The data on socio-demographic characteristics of the
Moroccan population are important to describe, they may
explain some Qol aspects. About one third of patients were
less than 50 years old, the median age at diagnosis was com-
parable to the one found in a study assessing quality of life
of Malaysian colorectal cancer patients [7] but it was lower
than the European average [8]. There was also a slight male
predominance, which is in agreement with other studies
[7–9]. This study reports the socio-economic characteristics
of Moroccan colorectal cancer patients; they are consistent
with the results of previous studies examining psychosocial
characteristics of Moroccan cancer patients [10, 11]. Most
of patients are illiterate, have low income. However the rate
of medical insurance is higher in this study (40 %) while it
was not exceeding 15 % in previous Moroccan cohorts
[10, 11], this could be explained by a new health policy of
the Moroccan government. Moreover, majority of patients
came from urban areas (78 %), in contradiction with previ-
ous studies where this rate was between 30 and 40 % [8, 9],
and this could be explained, by the availability of new struc-
tures treating cancers in most of Moroccan regions.
It was interesting to assess the quality of life of Moroc-
can cancer patients in this particular context of poverty
and illiteracy, while the health system, and in particular
management of cancer is improving. Another proof of
better fight against cancer is the diagnosis of colorectal
cancer at a non-metastatic stage in more than 60 % of
cases, while this percentage was previously found for
metastatic disease. However most of patients had a stage
III disease (66.3 %), which is comparable to the results of
Malaysian and Chinese studies [7, 12]. In developed coun-
tries, earlier stages, I and II, are the most frequent [13].
This could be explained by the absence of a screening pro-
gram in Morocco, in addition to the other socioeconomic
characteristics of Moroccan patients. The proportion of
rectal cancers (45 %) is high in this study, as it was re-
ported in Moroccan registries, in comparison with Euro-
pean studies. In a French cohort, examining colorectal
cancer quality of life, rectal cancer represented 36 % [1].
Table 3 Inclusion mean scores of functional dimensions according to sex, age, localization, stage and Performance status, among
colorectal cancer patients, Morocco, 2009–2011
Subgroup Global health status Physical function Role function Emotional function Cognitive function Social function
All 62.8499 71.6667 67.5641 65.6595 86.0051 81.9338
Localization
Colon 63.4199 70.6494 67.9825 68.7049* 86.5801 85.6061*
Rectum 62.0370 73.1308 66.9753 61.3169 85.1852 76.6975
p = 0.022 p = 0.005
Stage
I 66.6667 69.8148 74.0741 68.5185 91.6667 88.8889
II 68.3824 72.9657 67.1642 69.2402 89.9510 81.3725
III 60.3220* 71.3524 67.0476 63.9836 83.9015 81.4394
p = 0.003
Sex
Male 64,0443 71,4085 69,4836 67.4825 85.5478 83.3333
Female 61,4146 71,9748 65,2542 63.4687 86.5546 80.2521
Age
< 50 63.5294 74.5490* 71.7647 65.3595 85.2941 83.9216
50–60 63.5294 72.2603 65.9722 65.0304 89.2694 84.2466
60–69 62.9944 73.6782 70.3390 67.0904 85.3107 77.1186
≥ 70 58.8889 62.6667 58.3333 65.3704 82.9630 80.7407
p = 0.033
PS
< 1 70.2236* 80.8333* 79.2683* 69.9864 90.8537* 92.6829*
≥ 1 59.4907 67.4674 62.1723 63.6883 83.7963 77.0370
p < 0 .001 p < 0 .001 p < 0 .001 p < 0 .001 p < 0 .001
*: statistically significant
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Table 4 Inclusion mean scores of symptoms according to sex, age, localization, stage and Performance status, among colorectal
cancer patients, Morocco, 2009–2011
Subgroup Fatigue Nausea Pain Dyspnea Insomnia Anorexia Constipation Diarrhea Financial difficulties
All 38.2103 11.3868 30.1527 15.2672 32.3116 32.3116 20.4835 18.3206 61.7188
Localization
Colon 35.7504 8.9827* 25.3247* 13.4199 21.8615* 28.5714* 14.9351* 14.5022 62.6398
Rectum 41.7181 14.8148 37.0370 17.9012 35.1852 37.6947 28.3951 23.7654 60.4361
p =0.028 p =0.001 p =0.001 p = 0.024 p < 0.001 p = 0.006
Stage
I 37.0370 15.7407* 23.1481 11.1111 25.9259 29.6296 18.5185 18.5185 61.1111*
II 35.8660 4.4118 26.7157 12.2549 22.5490 28.9216 13.7255 18.1373 52.0202
III 39.2361 13.6364 32.1970 16.8561 29.3561 33.9048 23.2955 18.3712 65.5039
p = 0.006 p = 0.033
Sex
Male 36.2082 11.6550 27.3893 14.6853 26.3403 28.4038* 18.1818 19.8135 61.2293
Female 40.6162 11.0644 33.4734 15.9664 36.9748 36.9748 23.2493 16.5266 62.3188
p = 0.032
Age
< 50 36.4052 13.1373 30.3922 16.4706 30.5882 35.3175 23.1373 18.0392 65.4618
50–60 36.5297 8.9041 27.3973 11.8721 27.3973 27.3973 17.3516 20.5479 60.0939
60–69 38.4181 11.2994 31.6384 13.5593 23.1638 34.4633 16.3842 16.9492 57.4713
≥ 70 44.0741 12.2222 32.2222 20.7407 26.6667 31.8519 25.9259 17.0370 62.8788
PS
< 1 26,8970* 6,5041* 20,5285* 11,3821* 17.0732 24.7967* 11.7886* 15.4472 65.0407
≥ 1 43,3642 13,6111 34,5370 17,0370 32.0370 35.7542 24.4444 19.6296 60.1533
p < 0.001 p = 0.012 p < 0.001 p < 0.001 p = 0.01 p = 0.001
*: statistically significant
Fig. 1 QLQ C30 functional scores before and after treatment by chemotherapy, among colorectal cancer patients, Morocco, 2009–2011
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At inclusion, the global health status was comparable
to an American population [9] and the EORTC reference
values [8]. However, it was lower than a Malaysian
population. (See Table 5).
Physical, role and emotional functions scores are
lower than those of other populations but they remain
close to the EORTC reference values [8]. All these pa-
rameters may be related, to the socioeconomic status of
Moroccan patients.
The social function score is well above American
and European ones [1, 8, 9]. This could be due to the
Moroccan culture that promotes social and family re-
lationships [10, 11].
The financial difficulties are, by far, more present in
the Moroccan population. This is because of the low so-
cioeconomic status and the lack of medical insurance.
The lowest score are found in the European’s, whose
health system is very well designed [1, 8].
The other symptoms scores are higher than those of
the Malaysian population, in spite of the fact that the
Malaysian study included stage IV colorectal cancer [7].
Moroccan scores are close to EORTC reference values
except for nauseas, pain and appetite losses, suggesting a
need for better supportive care for our patients.
Emotional and social functions were significantly worse
in rectal cancer. Most symptoms were more present in
Fig. 2 QLQ C30 symptoms scores before and after treatment by chemotherapy, among colorectal cancer patients, Morocco, 2009–2011
Fig. 3 QLQ C30 functional scores before and after treatment by radiotherapy, among colorectal cancer patients, Morocco, 2009–2011
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rectal cancer. The difference was statistically significant
for Nauseas, pain, insomnia, anorexia, constipation and
diarrhea. At inclusion, global health status score was
significantly worse in stage III. Anorexia was the only par-
ameter which was significantly more important among
colorectal female patients. A german study, didn’t find
significant differences, between patients with colon and
rectal cancer, neither differences between male nor female
[13]. An Austrian study focused on the Qol impact of gen-
der and found no gender-specific reaction to disease [14].
For Patients over 70 years-old, the difference was sta-
tistically significant for the physical function item which
was lower. The influence of age on the impact of the dis-
ease is equivocal. Older people certainly have a higher
morbidity associated with the disease. However, studies
have shown that they better accept the deterioration of
their health. Younger patients may be more impaired
quality of life especially in relation to the psychological
impact of the disease and some symptoms that are seen
more significantly [13]. In our study, patients less than
50 years-old had higher scores of nauseas and insomnia.
Overall, Functional dimensions scores were improved
after the end of chemotherapy. The symptoms scores
did not differ significantly for patients treated by radio-
therapy, between inclusion and at one year. When we
look to the evolution of QOL scores every three months:
overall, functional dimensions and symptoms were stable
at 12 weeks and have started to improve thereafter, so
even during treatments, as chemotherapy or radiotherapy,
the QOL was maintained. Nausea was the only symptom
Fig. 4 QLQ C30 symptoms scores before and after treatment by radiotherapy, among colorectal cancer patients, Morocco, 2009–2011
Fig. 5 Evolution of functional dimensions every three months
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that worsened at 12 weeks and improved thereafter, since
it is the main symptom of which patients undergoing
chemotherapy complain. This finding is consistent with a
german study, where adjuvant chemotherapy didn’t alter
long term’s quality of life of early colorectal cancer
patients, at one year [13]. In the subgroup treated by adju-
vant chemotherapy, a significant improvement was seen
in the global health status, role function, fatigue, pain,
anorexia, constipation and diarrhea [13]. Several studies
showed that with actual management of adjuvant chemo-
therapy, the Qol can decrease during treatement, but in a
non statistiscally significant manner. However patients
quickly recover their quality of life scores before treatment
within a few months after completion of therapy [15, 16].
In the radiotherapy subgroup, the only significant
change for functional dimensions was observed in the
cognitive function. Unfortunately, we could not find any
reasonable explanation. Moreover, constipation was sig-
nificantly and largely improved, according to EORTC
criteria [17–19]. Pre-operative radiotherapy or chemora-
diation didn’t impact quality of life of early colorectal
cancer patients. The main limitation of this study is the
lack of Qol assessment before surgery, mainly for colon
cancer. QOL effects seen could be due to the surgery or
Fig. 6 Evolution of symptoms every three months
Table 5 Comparison of QLQ-C30 scores at inclusion between Moroccan colorectal cancer patients and patients of three others
populations
Item Moroccan population Malaysian population American population EORTC reference values
Global health status 62.8 79 62.6 60.7
Physical function 71 83 78.6 79.2
Role function 67 79 70.3 70.4
Emotional function 65.65 86.4 70.6 68.9
Cognitive function 86 92.2 79.7 85.2
Social function 81 88.2 68.4 76
Fatigue 38.2 16.6 38.8 34.7
Nauseas 11.3 4 13.4 7.3
Pain 30.15 17.2 29.3 24
Dyspnea 15.26 8.7 19.5 17.4
Insomnia 32.3 20.7 33.7 30.5
Appetite loss 32.6 18 25.2 19.1
Constipation 20.4 8.67 17.5 15.8
Diarrhea 18.3 10.3 15.4 16.6
Financial difficulties 61.7 26 32.5 13.6
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the subsequent treatments. The strengths of the reported
study are in related with its multicentre characteristic,
including all Moroccan oncology centers and using a
reliable tool of quality of life assessment.
Conclusion
This study shows that Moroccan colorectal cancer pa-
tients are a young population. A screening program and
more generalized medical insurance may help diagnosing
colorectal cancer at an earlier stage. QLQ C30 scores are
overall comparable to the EORTC QLQ C30 reference
values except for some symptoms, which could be im-
proved by more supportive care. Neither chemotherapy,
nor radiotherapy worsened the long term quality of life
of early colorectal cancer patients. The management of
colorectal cancer, in addition to specific treatments,
must take into account the patients quality of life, to
overcome some insufficiencies.
Abbreviations
EORTC: European organization for Research and treatment of Cancer;
PS: Performance status; QOL: Quality of life
Acknowledgments
To The Foundation Lalla Salma-Prevention and treatment of cancer and
“Roche Laboratories” for their support.
Availability of data and materials
All questionnaires and consents forms are available in various oncology
centers where the study was conducted. The data were pooled and
analyzed at the department of Epidemiology and Public health, Faculty
of Medicine, in Fez- Morocco.
Authors’ contributions
HM has contributed to conception and design, acquisition of data, analysis
and interpretation of data, wrote the manuscript; MA have been involved in
drafting the manuscript; IE has contributed to acquisition of data; YB has
contributed to acquisition of data; NB has contributed to acquisition of data;
HA has contributed to acquisition of data; SB has contributed to acquisition
of data; SF has contributed to conception and design, acquisition of data,
analysis and interpretation of data, CN has contributed to conception and
design, analysis and interpretation of data, has been involved in revising
critically the manuscript for important intellectual content and has given
final approval of the version to be published; AB has made substantial
contributions to conception and design of data; NM has contributed to
acquisition of data, OM has contributed to acquisition of data; MB has
contributed to conception and design of data; RB has contributed to
conception and design of data; AZ has contributed to conception and
design; HE has contributed to conception and design of data, acquisition of
data, has been involved in revising critically the manuscript for important
intellectual content and has given final approval of the version to be
published. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
This study has been approved by the ethics committee of the University
Hospital Center Hassan II in Fez- Morocco.
A written informed consent was required for enrolment in the study.
Author details
1Department of Medical Oncology, National Institute of Oncology, University
Hospital, Rabat, Morocco. 2Department of Epidemiology and Public health,
Faculty of Medicine, Fez, Morocco. 3Department of Radiotherapy, Ibn Rochd
University Hospital, Casablanca, Morocco. 4Department of Medical Oncology,
Hassan II University Hospital, Fez, Morocco. 5Lalla Salma
Foundation-Prevention and Treatment of Cancers, Rabat, Morocco.
Received: 25 July 2015 Accepted: 18 June 2016
References
1. Caravati-Jouvenceaux A, Launoy G, Klein D, Henry-Amar M, Abeilard E,
Danzon A, Pozet A, Velten M, Mercier M. Health-related quality of life
among long-term survivors of colorectal cancer: a population-based study.
Oncologist. 2011;16(11):1626–36.
2. Cancer Registry of Grand Casablanca region: 2005-2006-2007. Edition 2012
3. Nejjari C, El Fakir S, Bendahhou K, El Rhazi K, Abda N, Zidouh A, Benider A,
Errihani H, Bekkali R. Translation and validation of European organization for
research and treatment of cancer quality of life questionnaire -C30 into
Moroccan version for cancer patients in Morocco. BMC Res Notes. 2014;7:228.
4. El Fakir S, Abda N, Bendahhou K, Zidouh A, Bennani M, Errihani H, Benider A,
Bekkali R, Nejjari C. The European Organization for Research and Treatment of
Cancer quality of life questionnaire-BR23 Breast Cancer-Specific Quality of Life
Questionnaire: psychometric properties in a Moroccan sample of breast cancer
patients. BMC Res Notes. 2014;7:53.
5. Beaton D, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of
cross-cultural adaptation of self-report measures. SPINE. 2000;25(24):3186–91.
6. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et
al. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European
Organisation for Research and Treatment of Cancer; 2001.
7. Natrah MS, Ezat Sharifa WP, Syed MA, Rizal Mohd MA, Saperi S. Quality of
life in Malaysian colorectal cancer patients: a preliminary result. Asian Pacific
J Cancer Prev. 2012;13:957–62.
8. Neil W Scott, Peter M Fayers, Neil K Aaronson, Andrew Bottomley, Alexander
de Graeff, Mogens Groenvold, Chad Gundy, Michael Koller, Morten A Petersen,
Mirjam AG « EORTC QLQ-C30 Reference Values ».EORTC Quality of Life group
July 2008.
9. Braun Braun DP, Gupta D, Grutsch JF. Can changes in health related
quality of life scores predict survival in stages III and IV colorectal cancer?
Health Qual Life Outcomes. 2011;9:2–8.
10. Errihani H, Mrabti H, Sbitti Y, Kaikani W, El Ghissassi I, Afqir S, Boutayeb S,
Farik M, Riadi A, Hammoudi M, Chergui H. Psycho-social and religious
impact of cancer diagnosis on Moroccan patients: experience from the
National Oncology Center of Rabat. Bull Cancer. 2010;97(4):461–8.
11. Errihani H, Mrabti H, Boutayeb S, El Ghissassi I, El Mesbahi O, Hammoudi M,
Chergui H, Riadi A. Impact of cancer on Moslem patients in Morocco.
Psychooncology. 2008;17(1):98–100.
12. Peng J, Shi D, Goodman KA, Goldstein D, Xiao C, Guan Z, Cai S. Early results
of quality of life for curatively treated rectal cancers in Chinese patients with
EORTC QLQ-CR29. Radiat Oncol. 2011;6:93.
13. Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H. Quality of life in patients
with colorectal cancer 1 year after diagnosis compared with the general
population: a population-based study. J Clin Oncol. 2004;22:4829–36.
14. Giesinger J1, Kemmler G, Mueller V, Zabernigg A, Mayrbaeurl B, Thaler J,
Ofner D, Pegger C, Rumpold G, Weber B, Sperner-Unterweger B, Holzner B.
Are gender-associated differences in quality of life in colorectal cancer patients
disease-specific? Qual Life Res. 2009 Jun;18(5):547–55. doi: 10.1007/s11136-009-
9468-0. Epub 2009 Apr 1.
15. Zaniboni A, Labianca R, Marsoni S, et al.: GIVIO-SITAC 01: A randomized trial
of adjuvant 5-fluorouracil and folinic acid administered to patients with
colon carcinoma—long term results and evaluation of the indicators of
healthrelated quality of life.
16. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia
Adiuvante Colon. Cancer. 1998;82(34):2135–44.
17. Guren MG, Dueland S, Skovlund E, et al. Quality of life during radiotherapy
for rectal cancer. Eur J Cancer. 2003;39:587–594.
18. Uwer L, Rotonda C, Guillemin F, Miny J, Kaminsky M-C, Mercier M, Tournier-
Rangeard L, Leonard I, Montcuquet P, Rauch P, Conroy T. Responsiveness of
EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in
patients with colorectal cancer. Health Qual Life Outcomes. 2011;9:70.
19. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of
changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.
Mrabti et al. BMC Gastroenterology  (2016) 16:131 Page 10 of 10
